Skip to main content
. 2026 Apr 23;17:5648. doi: 10.1038/s41467-026-72203-3

Fig. 5. CD34/LNP-CAR mRNA induces CAR-CD34+ HSPCs to gather at the aortic lesion and inhibit the development of TAAD.

Fig. 5

a Bioluminescence imaging was conducted at 12 h and 24 h following saline, LNP-CAR mRNA, CD34/LNP-VEGFA mRNA, and CD34/LNP-CAR mRNA treatment, respectively. b The intensity of bioluminescence in the aorta at 12 h was analyzed. Data in (b) are from n = 3 biologically independent samples. c The intensity of bioluminescence in the liver, spleen, and lung at 12 h was analyzed. Data in (c) are from n = 3 biologically independent samples. d Schematic scheme of the experimental design to assess the therapeutic effect of CD34/LNP-CAR mRNA in the BAPN-induced TAAD murine model. Created in BioRender. Zhao, K. (2024) https://BioRender.com/z57v924. e Body weight changes during model induction. Data in (e) are from n = 3 biologically independent samples. f The Kaplan-Meier survival probability curve for the four groups. Data in (f) are from n = 12 biologically independent samples. g Representative echocardiographic images. h Data analysis of the maximum aortic diameter. Data in (h) are from n = 3 biologically independent samples. i The representative gross anatomy images of mice. j The incidence of TAAD. Data in (i) are from n = 3 independent experiments. All data are presented as mean ± s.d. Statistical significance and P-values of (b), and (j) were analyzed by using one-way ANOVA followed by Tukey’s multiple comparisons test (two-sided). Statistical significance and P-values of (c, e, and h) were analyzed by using two-way ANOVA followed by Tukey’s multiple comparisons test (two-sided). Data of (f) were analyzed by using the Kaplan–Meier method and compared by the log-rank (Mantel-Cox) test. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file.